House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Pulmonology

Idiopathic pulmonary fibrosis in adults: diagnosis and management

NICE · 2017 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE CG163 provides an adult idiopathic pulmonary fibrosis pathway from recognition and multidisciplinary diagnosis through rehabilitation, symptom relief, transplant discussion and follow-up. It links disease-modifying treatment to separate NICE technology appraisals, including a later nintedanib update. This summary reflects the captured recommendations and their UK context; it is not a complete catalogue of all currently available antifibrotic therapies.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish the diagnosis through an experienced team

  • Consider IPF with persistent exertional breathlessness or cough, bilateral inspiratory crackles and finger clubbing, particularly above age 45. Spirometry may be normal, restrictive or occasionally obstructive. [1]
  • Assess suspected IPF with history, examination and blood tests to exclude alternatives, including exposure-related, connective-tissue and drug-related disease. Obtain spirometry and gas transfer, review the chest radiograph and perform thoracic CT with high-resolution images. [1]
  • Make the diagnosis by multidisciplinary consensus using clinical features, lung function, radiology and pathology when indicated. The team needs interstitial-lung-disease expertise; specialist pathology and surgical input become relevant when invasive investigations are considered. [1]
  • If the diagnosis remains uncertain, discuss the potential value and greater risks of surgical biopsy compared with lavage or transbronchial biopsy. Consider the differential diagnosis and comorbidities, and continue specialist review if confidence remains insufficient. [1]

Explain the illness and measure change

  • Provide clear verbal and written information about investigations, diagnosis and care, with access to an interstitial-lung-disease specialist nurse throughout the pathway. Involve family with consent and offer smoking-cessation support. [1]
  • Measure lung function at diagnosis and at 6 and 12 months to assess decline, using shorter intervals for suspected rapid deterioration. Discuss variable disease courses and prognosis sensitively; do not use baseline six-minute walk distance alone to estimate prognosis. [1]
  • Assess suitability for pulmonary rehabilitation at diagnosis and again every 6 or 12 months. Offer exercise and education when appropriate, tailored to the individual and accessible to people with disability. [1]

Start supportive care at diagnosis

  • Offer supportive care from diagnosis according to severity, progression and preference. Include symptom relief, comorbidity management, withdrawal of ineffective or harmful treatments and end-of-life care when appropriate. [1]
  • For exertional breathlessness, consider assessment of the cause, hypoxia, oxygen needs and rehabilitation. Breathlessness at rest also warrants assessment of psychosocial needs and possible palliative referral, with consideration of opioid and/or benzodiazepine symptom relief. [1]
  • Before discharge after an IPF admission, assess oxygen requirements. Be alert to limitations of pulse oximetry, including possible overestimation in people with dark skin, especially when readings are borderline. [1]
  • For cough, evaluate other causes such as reflux or postnasal drip; consider opioids when cough is debilitating. Ensure access to palliative services and coordination with community and specialist teams. [1]

Use the relevant disease-modifying appraisal and discuss transplant

  • The captured guideline points to nintedanib appraisal TA864 for FVC above 80% predicted, and to pirfenidone TA504 or nintedanib TA379 for FVC between 50% and 80% predicted. Consult the complete applicable appraisal for eligibility and conditions rather than using these ranges as a complete prescribing rule. [1]
  • Do not use ambrisentan, azathioprine, bosentan, co-trimoxazole, mycophenolate, prednisolone, sildenafil or warfarin to modify IPF progression. If someone is already taking prednisolone or azathioprine, discuss the benefits and harms of stopping, continuing or changing treatment. [1]
  • Discuss transplantation within 3–6 months of diagnosis, or earlier when indicated, with people without absolute contraindications. Include risks and benefits and specialist-nurse support; refer those who wish to explore it, seeking an initial transplant-centre response within 4 weeks. [1]
  • Discuss the poor outcomes associated with invasive and non-invasive mechanical ventilation, ideally within 3–6 months or sooner if indicated. NICE advises against routinely offering it for life-threatening respiratory failure in IPF; decisions need the individual care context. [1]

Adjust review frequency to progression

  • At follow-up assess lung function, oxygen and rehabilitation needs, exacerbations and admissions, comorbidities, psychosocial concerns and possible transplant or palliative referral. Continue smoking-cessation support. [1]
  • Consider review every 3 months or sooner for rapid progression, every 6 months or sooner for steadily progressive disease, and initially every 6 months for stable disease, extending to yearly if stable after one year. [1]

Limitations and use

  • This summary follows the captured NICE CG163 text and its linked technology-appraisal references. It does not independently establish the complete current international or Indian antifibrotic treatment landscape, local availability or reimbursement.
  • The full linked drug appraisals, contraindications, doses and monitoring requirements are not reproduced. Its progression-modifying drug restrictions do not prohibit treatment of a separate comorbidity for an appropriate indication.
  • Biopsy decisions, transplantation eligibility and respiratory-failure management require the specialist multidisciplinary context; this is not an acute-exacerbation or transplant protocol.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Idiopathic pulmonary fibrosis in adults: diagnosis and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
12 June 2013
Publisher’s latest update
23 May 2017
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish the diagnosis through an experienced team
  • Explain the illness and measure change
  • Start supportive care at diagnosis
  • Use the relevant disease-modifying appraisal and discuss transplant
  • Adjust review frequency to progression
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House